DPP-4 inhibition has beneficial effects on the heart after myocardial infarction

Journal of Molecular and Cellular Cardiology

Volumn 91, Issue , 2016, Pages 72-80

  Kubota, Akihiko ^a   Takano, Hiroyuki ^b   Wang, Haixiu ^b   Hasegawa, Hiroshi ^a   Tadokoro, Hiroyuki ^c   Hirose, Masanori ^a   Kobara, Yuka ^a   Yamada Inagawa, Tomoko ^b   Komuro, Issei ^d   Kobayashi, Yoshio ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Apoptosis; DPP 4; Heart failure; Myocardial infarction; STAT3

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; MK 0626; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; CXCR4 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL HYPOXIA; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; GENE DELETION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; LEFT CORONARY ARTERY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; TUNEL ASSAY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CARDIOTONIC AGENTS; CHEMOKINE CXCL12; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VENTRICULAR FUNCTION, LEFT;

EID: 84953290743     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.12.026     Document Type: Article

References (36)

1. Ramani G.V., Uber P.A., Mehra M.R. Chronic heart failure: contemporary diagnosis and management. Mayo Clin. Proc. 2010, 85:180-195.
2. Ueda K., Takano H., Niitsuma Y., Hasegawa H., Uchiyama R., Oka T., Miyazaki M., Nakaya H., Komuro I. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J. Clin. Invest. 2010, 120:2016-2029.
3. Owens A.T., Jessup M. The year in heart failure. J. Am. Coll. Cardiol. 2012, 60:359-368.
4. Abete P., Testa G., Della-Morte D., Gargiulo G., Galizia G., de Santis D., Magliocca A., Basile C., Cacciatore F. Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail. Rev. 2013, 18:529-551.
5. Jackson E.K. Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome. Hypertension 2010, 56:581-583.
6. Avogaro A., de Kreutzenberg S., Fadini G. Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection. Curr. Pharm. Des. 2014, 20:2387-2394.
7. Yin M., Silljé H.H., Meissner M., van Gilst W.H., de Boer R.A. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc. Diabetol. 2011, 10:85.
8. Hausenloy D.J., Whittington H.J., Wynne A.M., Begum S.S., Theodorou L., Riksen N., Mocanu M.M., Yellon D.M. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc. Diabetol. 2013, 12:154.
9. Szmitko P.E., Leiter L.A., Verma S. The incretin system and cardiometabolic disease. Can. J. Cardiol. 2010, 26:87-95.
10. Hu X., Dai S., Wu W.J., Tan W., Zhu X., Mu J., Guo Y., Bolli R., Rokosh G. Stromal cell-derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell-derived factor-1 alpha-CXCR4 axis. Circulation 2007, 116:654-663.
11. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S., Kishimoto T., Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-594.
12. Shigeta T., Aoyama M., Bando Y.K., Monji A., Mitsui T., Takatsu M., Cheng X.W., Okumura T., Hirashiki A., Nagata K., Murohara T. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012, 126:1838-1851.
13. Zaruba M.M., Theiss H.D., Vallaster M., Mehl U., Brunner S., David R., Fischer R., Krieg L., Hirsch E., Huber B., Nathan P., Israel L., Imhof A., Herbach N., Assmann G., Wanke R., Mueller-Hoecker J., Steinbeck G., Franz W.M. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009, 4:313-323.
14. Bhattacharjee A., Allister E.M., Wheeler M.B. MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice. Can J. Physiol. Pharmacol. 2012, 90:663-668.
15. Takasawa W., Ohnuma K., Hatano R., Endo Y., Dang N.H., Morimoto C. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem. Biophys. Res. Commun. 2010, 401:7-12.
16. Kayama H., Ueda Y., Sawa Y., Jeon S.G., Ma J.S., Okumura R., Kubo A., Ishii M., Okazaki T., Murakami M., Yamamoto M., Yagita H., Takeda K. Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:5010-5015.
17. Ku H.C., Chen W.P., Su M.J. DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes. PLoS ONE 2013, 8.
18. Askari A.T., Unzek S., Popovic Z.B., Goldman C.K., Forudi F., Kiedrowski M., Rovner A., Ellis S.G., Thomas J.D., DiCorleto P.E., Topol E.J., Penn M.S. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
19. Saxena A., Fish J.E., White M.D., Yu S., Smyth J.W., Shaw R.M., DiMaio J.M., Srivastava D. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 2008, 117:2224-2231.
20. Huang C., Gu H., Zhang W., Manukyan M.C., Shou W., Wang M. SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H1496-H1505.
21. Harada M., Qin Y., Takano H., Minamino T., Zou Y., Toko H., Ohtsuka M., Matsuura K., Sano M., Nishi J., Iwanaga K., Akazawa H., Kunieda T., Zhu W., Hasegawa H., Kunisada K., Nagai T., Nakaya H., Yamauchi-Takihara K., Komuro I. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-stat pathway in cardiomyocytes. Nat. Med. 2005, 11:305-311.
22. Angeli F.S., Amabile N., Shapiro M., Mirsky R., Bartlett L., Zhang Y., Virmani R., Chatterjee K., Boyle A., Grossman W., Yeghiazarians Y. Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction. Cardiovasc. Drugs Ther. 2010, 24:409-420.
23. Duez H., Cariou B., Staels B. DPP-4 inhibitors in the treatment oftype 2 diabetes. Biochem. Pharmacol. 2012, 83:823-832.
24. Broxmeyer H.E., Hoggatt J., O'Leary H.A., Mantel C., Chitteti B.R., Cooper S., Messina-Graham S., Hangoc G., Farag S., Rohrabaugh S.L., Ou X., Speth J., Pelus L.M., Srour E.F., Campbell T.B. Dipeptidyl peptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat. Med. 2012, 18:1786-1796.
25. Sauvé M., Ban K., Momen M.A., Zhou Y.Q., Henkelman R.M., Husain M., Drucker D.J. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010, 59:1063-1073.
26. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor- dependent and -independent pathways. Circulation 2008, 117:2340-2350.
27. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10:858-864.
28. Dang D.T., Chun S.Y., Burkitt K., Abe M., Chen S., Havre P., Mabjeesh N.J., Heath E.I., Vogelzang N.J., Cruz-Correa M., Blayney D.W., Ensminger W.D., St Croix B., Dang N.H., Dang L.H. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res. 2008, 68:1872-1880.
29. Kanki S., Segers V.F., Wu W., Kakkar R., Gannon J., Sys S.U., Sandrasagra A., Lee R.T. Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. Circ. Heart Fail. 2011, 4:509-518.
30. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol. Sci. 2009, 30:600-607.
31. Huang C., Gu H., Zhang W., Manukyan M.C., Shou W., Wang M. SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:1496-1505.
32. Haghikia A., Ricke-Hoch M., Stapel B., Gorst I., Hilfiker-Kleiner D. STAT3, a key regulator of cell-to-cell communication in the heart. Cardiovasc. Res. 2014, 102:281-289.
33. Ferreira L., Teixeira-de-Lemos E., Pinto F., Parada B., Mega C., Vala H., Pinto R., Garrido P., Sereno J., Fernandes R., Santos P., Velada I., Melo A., Nunes S., Teixeira F., Reis F. Effects of sitagliptin treatment on dysmetabolisminflammation, and oxidative stress in an animal model of type 2 diabetes. Mediat. Inflamm. 2010, 2010:592760.
34. Scirica B.M., Bhatt D.L. Braunwald E, Steg PG, Davidson J, hirshberg B, ohman P, frederich R, wiviott SD, Hoffman EB, cavender MA, udell JA, Desai NR, mosenzon O, McGuire DK, ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 steering committee and investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013, 369:1317-1326.
35. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., Perez A.T., Fleck P.R., Mehta C.R. Kupfer S, Wilson C, Cushman WC, zannad F; EXAMINE investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013, 369:1327-1335.
36. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., Josse R., Kaufman K.D., Koglin J., Korn S., Lachin J.M., McGuire D.K., Pencina M.J., Standl E., Stein P.P., Suryawanshi S., Van de Werf F., Peterson E.D., Holman R.R., TECOS Study Group Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2015, 373:232-242.